Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, gives an outline of the data she will be presenting at WCLC 2021. Dr Johnson will give an update on the Phase I/II PROCLAIM-CX-2029 trial (NCT03543813) investigating the CD71-directed antibody-drug conjugate CX-2029 in squamous cell lung cancer, gastric cancer and head and neck cancer. She will also share some new data from a trial of AMG 757, a DLL3-targeted bispecific T-cell engager (BiTE), in adults with small cell lung cancer (NCT03319940). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

свернуть